Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group

Prostate cancer is a significant public health burden and a major cause of morbidity and mortality among men worldwide. Analyzing geographic patterns and temporal trends may help identify high‐risk populations, suggest the degree of PSA testing, and provide clues to etiology. We used incidence data available from the International Agency for Research on Cancer (IARC) and certain cancer registries for 43 populations across five continents during a median period of 24 years. Trends in overall prostate cancer rates showed five distinct patterns ranging from generally monotonic increases to peaking of rates followed by declines, which coincide somewhat with changes in the prevalence of PSA testing. Trends in age‐specific rates generally mirrored those in the overall rates, with several notable exceptions. For populations where overall rates increased rapidly and then peaked, exemplified in North America and Oceania, the highest incidence tended to be most pronounced and occurred during earlier calendar years among older men compared with younger ones. For populations with almost continual increases in overall rates, exemplified in Eastern Europe and Asia, peaks were evident among men aged ≥75 years in many instances. Rates for ages 45–54 years did not clearly stabilize or decline in the majority of studied populations. Global geographic variation remained substantial for both overall and age‐specific incidence rates regardless of levels of PSA testing, with the lowest rates consistently in Asia. Explanations for the persistent geographic differences and the continuing increases of especially early‐onset prostate cancer remain unclear.

[1]  Pamela A. Shaw,et al.  Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. , 2002, Urology.

[2]  N. Lawrentschuk,et al.  Population‐based analysis of prostate‐specific antigen (PSA) screening in younger men (<55 years) in Australia , 2014, BJU international.

[3]  B A Miller,et al.  The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.

[4]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[5]  Peter H Gann,et al.  Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.

[6]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[7]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[8]  K. Cooney,et al.  Prostate cancer in young men: an important clinical entity , 2014, Nature Reviews Urology.

[9]  S. Taneja,et al.  Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. , 2009, Reviews in urology.

[10]  Lisa M. Schwartz,et al.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? , 2003, JAMA.

[11]  J. Blandy Geoffrey Duncan Chisholm , 1997 .

[12]  David C. Miller,et al.  Prostate Cancer Registries: Current Status and Future Directions. , 2016, European urology.

[13]  F. Bray,et al.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. , 2007, Journal of the National Cancer Institute.

[14]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[15]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[16]  L. Kessler,et al.  Rise in prostatic cancer incidence associated with increased use of transurethral resection. , 1990, Journal of the National Cancer Institute.

[17]  Jacques Ferlay,et al.  Cancer in Africa 2012 , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[18]  F. Hamdy,et al.  Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities , 2011, BJU international.

[19]  P. Stattin,et al.  Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol 2015;68:e110. , 2015, European urology.

[20]  S. Eggener,et al.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Schwartz,et al.  Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. , 1999, The Journal of urology.

[22]  S. Naito,et al.  Japanese Urological Association guidelines on prostate‐specific antigen‐based screening for prostate cancer and the ongoing cluster cohort study in Japan , 2008, International journal of urology : official journal of the Japanese Urological Association.

[23]  E. Schernhammer,et al.  Prostate cancer and prostate-specific antigen (PSA) screening in Austria , 2005, Wiener klinische Wochenschrift.

[24]  Patrick C. Walsh,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[25]  M. Barry,et al.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.

[26]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[27]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[28]  T. Fears,et al.  Graphical presentation of trends in rates. , 1995, American journal of epidemiology.

[29]  Seth Falcon,et al.  Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  Curtis Mettlin,et al.  Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers , 1993, CA: a cancer journal for clinicians.

[31]  T. Thompson,et al.  Recent trends in prostate cancer testing and incidence among men under age of 50. , 2012, Cancer epidemiology.

[32]  J. Onysko,et al.  Lifetime and Recent Prostate Specific Antigen (PSA) Screening of Men for Prostate Cancer in Canada , 2006, Canadian journal of public health = Revue canadienne de sante publique.

[33]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[34]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[35]  J. Ferlay,et al.  Prostate cancer incidence and mortality trends in 37 European countries: an overview. , 2010, European journal of cancer.

[36]  H. Yasunaga,et al.  Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010 , 2010, International journal of urology : official journal of the Japanese Urological Association.

[37]  J. Witjes,et al.  Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. , 2013, Family practice.

[38]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[39]  S. Moss,et al.  Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. , 1997, British journal of urology.

[40]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[41]  Sam S. Chang,et al.  Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. , 2015, The Journal of urology.

[42]  S. Moss,et al.  Survey of the rate of PSA testing in general practice , 2001, British Journal of Cancer.

[43]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[44]  Bey P Le [Cancer in Africa]. , 2013, Bulletin du cancer.

[45]  E. Feuer,et al.  The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States , 1998, Cancer Causes & Control.

[46]  G. Smailytė,et al.  Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme. , 2012, Public health.

[47]  G Bartsch,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.

[48]  S. Rosso,et al.  Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  栗原 登,et al.  Trends cancer mortality for selected sites in 24 countries , 1960 .

[50]  M. Freedman,et al.  Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa , 2009, Infectious Agents and Cancer.

[51]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[52]  P. Walsh,et al.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. , 1993, The Journal of urology.